Successful multi-target therapy including rituximab and mycophenolate mofetil in anti-melanoma differentiation-associated gene 5 antibody-positive rapidly progressive interstitial lung disease with clinically amyopathic dermatomyositis

Int J Rheum Dis. 2017 Dec;20(12):2182-2185. doi: 10.1111/1756-185X.13136. Epub 2017 Jul 27.

Authors

Jumpei Hisanaga¹, Takuya Kotani¹, Youhei Fujiki¹, Shuzo Yoshida¹, Tohru Takeuchi¹, Shigeki Makino¹

Affiliation

¹ Department of Internal Medicine IV, Osaka Medical College, Takatsuki, Osaka, Japan.

PMID: 28752606
DOI: 10.1111/1756-185X.13136

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Autoantibodies / blood
Autoantibodies / immunology*
Dermatomyositis / diagnosis
Dermatomyositis / drug therapy*
Dermatomyositis / immunology
Drug Therapy, Combination
Female
Hemoperfusion / methods
Humans
Immunoglobulins, Intravenous / therapeutic use
Immunosuppressive Agents / therapeutic use*
Interferon-Induced Helicase, IFIH1 / immunology*
Lung Diseases, Interstitial / diagnosis
Lung Diseases, Interstitial / drug therapy*
Lung Diseases, Interstitial / immunology
Middle Aged
Mycophenolic Acid / therapeutic use*
Remission Induction
Rituximab / therapeutic use*
Tomography, X-Ray Computed
Treatment Outcome

Substances

Autoantibodies
Immunoglobulins, Intravenous
Immunosuppressive Agents
Rituximab
IFIH1 protein, human
Interferon-Induced Helicase, IFIH1
Mycophenolic Acid

Supplementary concepts

Amyopathic dermatomyositis